SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPDR S&P 500 ETF is surging as comments from Donald Trump about the Iran conflict being "very complete, pretty much" trigger a broad market rebound, though many in the community are highly skeptical, calling it a "Trump pump" or "manipulation" and questioning the true de-escalation given ongoing geopolitical tensions. The rapid turnaround has sparked intense debate over the market's current volatility and underlying catalysts.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is highly volatile amid escalating Middle East tensions threatening global oil supply, while conflicting statements from former President Trump suggesting the conflict is "very complete" are causing sharp, contentious reversals. The market remains deeply divided on whether sustained geopolitical risks will outweigh potential de-escalation and strategic reserve releases.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending after reporting strong quarterly results driven by significant MIPLYFFA revenue, which exceeded expectations and signals a commercial breakthrough, fueling community discussions around future profitability, anticipated European approval, and the impact of a new CFO hire.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is surging, fueling a significant short squeeze, after reports of President Trump's optimistic statements suggested the Iran war is 'very complete, pretty much,' leading to a market rebound and a sharp drop in oil prices amid divided investor sentiment.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as escalating geopolitical tensions, particularly concerning a potential conflict involving Iran and its impact on rising oil prices, are driving widespread market fear and discussions of increased volatility. The community is actively debating whether to accumulate UVIX as a hedge against a market correction or if these events are already priced into the market amid perceived manipulation.

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

Terrestrial Energy (IMSR) is gaining attention following a new DOE agreement for its IMSR Fuel Salt production pilot and recent positive analyst coverage with a $15 price target. The community actively discusses its Integral Molten Salt Reactor technology as a "dark horse" in the advanced nuclear sector, comparing its potential to peers like OKLO, especially given its strategic position to meet escalating AI data center energy demands.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as bullish investors highly anticipate imminent positive Phase 3 trial results for its AML immunotherapy, GPS, following the CEO's remarks hinting at "curative outcomes" and fueling intense speculation about a potential short squeeze and acquisition interest from major pharmaceutical companies.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Relmada Therapeutics Inc

Relmada Therapeutics is trending following positive 12-month Phase 2 interim data for its bladder cancer candidate NDV-01, which supports advancing to Phase 3, alongside an oversubscribed $160 million private placement financing. The community is vigorously discussing the biotech's significant price and volume surge, anticipating continued momentum for its promising clinical pipeline.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is trending as it begins early U.S. operations under a White House-backed eVTOL Integration Pilot Program and launches Uber Air in Dubai, marking significant progress toward commercial air taxi services. The community is actively discussing these milestones alongside recent positive earnings and ongoing comparisons with competitor Archer Aviation.

Hewlett Packard Enterprise Co. is a global edge-to-cloud company, which engages in the provision of information technology, technology and enterprise products, solutions, and services. It operates through the following segments: Server, Hybrid Cloud, Intelligent Edge, Financial Services, and Corporate Investments and Other. The Server segment consists of general-purpose servers for multi-workload computing and workload-optimized servers to deliver the performance and value for demanding applications, and integrated systems comprised of software and hardware designed to address high-performance computing and supercomputing, artificial intelligence, data analytics, and transaction processing workloads for government and commercial customers globally. The Hybrid Cloud segment is involved in a variety of cloud-native and hybrid solutions across storage, private cloud, and the infrastructure software-as-a-service space. The Intelligent Edge segment offers wired and wireless local area networks, campus, branch, and data center switching, software-defined wide-area-networks, private and public cellular network software, network security, and associated services that enable secure connectivity for businesses of any size. The Financial Services segment provides investment solutions, such as leasing, financing, IT consumption, utility programs, and asset management services for customers that facilitate technology deployment models and the acquisition of complete IT solutions, including hardware, software, and services from Hewlett Packard Enterprise and others. The Corporate Investments and Other segment includes the Advisory and Professional Services business, which primarily offers consultative-led services, HPE and partner technology expertise and advice, implementation services, as well as complex solution engagement capabilities, the Communications and Media Solutions business, which primarily offers software and related services to the telecommunications industry, and Hewlett Packard Labs, which is responsible for research and development. The company was founded by William R. Hewlett and David Packard on July 2, 1939 and is headquartered in Spring, TX.

Hewlett Packard Enterprise Co

HPE is trending as its recent earnings showcased strong demand for AI systems and significant growth in its networking segment, boosted by the completed Juniper Networks acquisition. The community is actively discussing the company's strategic shift to an AI-driven hybrid cloud and networking powerhouse, anticipating substantial market share gains despite lingering concerns about short-term outlooks and rising component costs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Buy: What Does It Mean for the Stock?

Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to...

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-CMA, HFWA, BRNS, and FITB

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-CMA, HFWA, BRNS, and FITB $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-CMA...

Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their...

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-CRTAF, AKRO, NIC, and BRNS

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-CRTAF, AKRO, NIC, and BRNS $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-CRTAF...

ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics

ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with...

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of Shareholders

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of Shareholders SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of...

Barinthus Biotherapeutics (BRNS) announced on Tuesday that it will merge with Clywedog Therapeutics in an all-stock transaction. Following the announcement, the company's shares slid 7% in the pre-market session.Under the deal, Barinthus Bio shareholders will receive one share of common stock in the new combined company for each American Depositary Share (ADS) or ordinary share they own. Meanwhile, each stockholder of Clywedog will receive 4.358932 shares of common stock in the new combined company for every common or preferred share they own. The combined company will advance a fresh portfolio of three clinical-stage candidates targeting metabolic and autoimmune diseases, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.barinthusbio.com/news-releases/news-release-details/barinthus-biotherapeutics-combine-clywedog-therapeutics-target">said</a>. Four clinical data milestones are expected within 18 months of transaction closing, it added.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BRNS">BRNS stock</a> rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.The combined company will be renamed “Clywedog Therapeutics, Inc.” and is expected to trade on the Nasdaq under the new ticker symbol “CLYD.” Barinthus Bio ADSs will no longer trade on the Nasdaq following the closing of the transaction in the first half of 2026.The combined company will initially focus on advancing its pipeline in Type 1 diabetes, Type 2 diabetes, and celiac disease, Barinthus said. It is expected to have a cash runway into 2027 with additional investments from Clywedog’s existing investors, OrbiMed and Torrey Pines Investment LLC.Upon closing, shareholders of Barinthus Bio are expected to own approximately 34%, and the stockholders of Clywedog are expected to own approximately 66% of the combined company on a fully diluted basis.BRNS shares are up by 22% this year and 24% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-gets-price-target-hike-from-canaccord/chDD7JrR3Bq">Tesla Gets A Price Target Hike From Canaccord: Retail Sees Stock Touching New Highs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Barinthus Biotherapeutics To Merge With Privately-Held Clywedog Therapeutics

Under the deal, Barinthus Bio shareholders will receive one share of common stock in the new combined company for each American Depositary Share or ordinary share they own.

Equity

Under the deal, Barinthus Bio shareholders will receive one share of common stock in the new combined company for each American Depositary Share or ordinary share they own.


Barinthus Biotherapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. It also focuses on the pipeline of both clinical and preclinical stage therapeutic, and prophylactic programs. The company was founded by Adrian Hill and Dame Sarah Gilbert in March 2021 and is headquartered in Didcot, the United Kingdom.

Current Price	$0.5621
Prev Close	$0.603
Open	$0.615
Dividend Yield	0.00%
50-Day Moving Average	$0.6848
Beta	0.75
Avg. Volume	70,971.32
PE Ratio	-0.32

52-Week High	$2.92
52-Week Low	$0.56
Market Capitalization	$24.62M
EPS (Annual)	-$1.55
Price to Book	0.29
Revenue Per Employee	$142,621.89

BRNS
Barinthus Biotherapeutics PLC - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BRNS News

BRNSBarinthus Biotherapeutics PLC - ADR